<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805398</url>
  </required_header>
  <id_info>
    <org_study_id>CM310NP001</org_study_id>
    <nct_id>NCT04805398</nct_id>
  </id_info>
  <brief_title>Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety, PK, PD and Immunogenicity of Subcutaneously Given Multiple-Dose CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keymed Biosciences Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keymed Biosciences Co.Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the&#xD;
      efficacy, safety, PK, PD and immumogenicity of CM310 in comparison to placebo in addition to&#xD;
      a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic&#xD;
      rhinosinusitis with nasal polyposis (CRSwNP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a Screening/run-in Period (up to 4 weeks), a Randomized, Double Blind&#xD;
      Treatment Period (16 weeks, till End-of-Treatment Visit) and a Safety Follow-up Period (8&#xD;
      weeks, till End-of-Study Visit).&#xD;
&#xD;
      56 patients who meet eligibility criteria will be randomized 1:1 to receive either CM310&#xD;
      300mg or matched placebo subcutaneously every two weeks (Q2W) for a total of 8 times. All&#xD;
      patients will receive MFNS on a daily basis as a background treatment throughout the study.&#xD;
      MFNS is required to use no less than 14 days during Screening/run-in Period.&#xD;
&#xD;
      Central reading will be implemented to nasal endoscopic nasal polyp score (NPS) , CT scans to&#xD;
      Lund-Mackay score and volume of the involved area of nasosinusitis on 3D-construction images,&#xD;
      and nasal polyp biopsy tissue analysis to eosinophil counts &amp; percentage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bilateral endoscopic Nasal Polyps Score (NPS)</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in the bilateral endoscopic NPS.NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal Congestion/Obstruction SymptomSeverity (NCS) Score</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in the NCS score. NCS score (0-3), higher score means worse nasal symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first response of NPS</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Time to the first response of NPS (defined as bilateral endoscopic NPS improved ≥1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lund-Mackay score</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in the Lund-Mackay score on CT scan. The range of LM score is 0-24. Higher score means worse nasosinusitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of the involved area of nasosinusitis on 3D-construction CT scan</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in the volume of the involved area of nasosinusitis on 3D-construction CT scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral endoscopic NPS</measure>
    <time_frame>at Week 8</time_frame>
    <description>Change from baseline in the bilateral endoscopic NPS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects receiving rescue therapy for nasal polyps</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Proportion of subjects receiving rescue therapy for nasal polyps.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in UPSIT. UPSIT score (0-40). Higher score means better sense of smell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>22-item Sino-nasal Outcome Test Scores(SNOT-22) score</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in SNOT-22 score. SNOT-22 score (0-110). Higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Score(TSS) score</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in TSS score. TSS score (0-9). Higher score means worse nasal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral endoscopic NPS</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in the bilateral endoscopic NPS in subjects with concurrent asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral endoscopic NCS</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline in the NCS in subjects with concurrent asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs), of treatment-emergent serious AEs (TESAEs), etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics(PK)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Trough concentration and exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics(PD)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in serum biomarker level (TARC, total IgE and eosinophil level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD(eosinophil level in nasal polyps biospy tissue)</measure>
    <time_frame>at Week 16</time_frame>
    <description>Change from baseline of eosinophil level in nasal polyps biospy tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies(ADA)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Incidence of ADA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody (Nab)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Incidence of Nab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>CM310</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CM310</intervention_name>
    <description>300 mg every two weeks</description>
    <arm_group_label>CM310</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>300 mg every two weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bilateral CRSwNP.&#xD;
&#xD;
          -  Prior treatment with systemic corticosteroids (SCS), and/or contraindicate to or&#xD;
             intolerance to SCS, and/or with prior surgery to nasal polyps.&#xD;
&#xD;
          -  Stable dose of intranasal corticosteroids for at least 4 weeks before screening.&#xD;
&#xD;
          -  Ongoing symptoms for at least 4 weeks before screening：1)Nasal congestion/obstruction;&#xD;
             2)Othe symptom, e.g., loss of smell or rhinorrhea.&#xD;
&#xD;
          -  Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity at screening and at&#xD;
             baseline.&#xD;
&#xD;
          -  NCS score of 2 or 3 at screening and at baseline.&#xD;
&#xD;
          -  Eosinophilic level meets the one of the following criteria: 1) serum eosinophil count&#xD;
             ≥6.9% (without concomitant asthma) or ≥3.7% (with concomitant asthma) at screening; 2)&#xD;
             absolute count of ≥55 per high power field or percentage of ≥27% in eosinophil level&#xD;
             from nasal polyps biospy tissue.&#xD;
&#xD;
          -  Contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not enough washingout period for previous therapy, e.g., less than 10 weeks or 5&#xD;
             half-lives (whichever is longer) for IL-4Rα antagonists, less than 8 weeks or 5&#xD;
             half-lives for biologic therapy/systemic immunosuppressant, less than 6 months for&#xD;
             sinus surgery (including polypectomy).&#xD;
&#xD;
          -  concurrent disease, e.g., ongoing rhinitis medicamentosa, acute sinusitis, nasal&#xD;
             infection or upper respiratory infection, allergic fungal rhinosinusitis, malignancy,&#xD;
             uncontrolled chronic disease such as cardivascular diseases, tuberculosis, diabetes&#xD;
             etc.&#xD;
&#xD;
          -  Allergic or intolerant to mometasone furoate spray or CM310/placebo.&#xD;
&#xD;
          -  Significant liver or renal dysfunction.&#xD;
&#xD;
          -  Other.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luo Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital, CMU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital, CMU</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Renmin Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital, CMU</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jingzhou Central Hospital</name>
      <address>
        <city>Jingzhou</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Second Provincial General Hospital (Shandong ENT hospital)</name>
      <address>
        <city>Jinan</city>
        <state>Shangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital of Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Chengdu University of Traditional Chinese Medicine</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Rhinosinusitis with Nasal Polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

